Reciprocal enhancement of gene transfer by combinatorial adenovirus transduction and plasmid DNA transfection in vitro and in vivo.

Abstract:

:The addition of replication-defective recombinant adenovirus to plasmid transfection (termed here "adenofection") has been shown to increase plasmid transgene expression in limited studies. Similarly, the addition of cationic liposomes to adenovirus increases adenovirus-mediated gene transduction (termed here "lipoduction"). Here we demonstrate that adenofection was effective at enhancing transgene expression when used in conjunction with a variety of different transfection reagents, including a monocationic liposome, a polycationic liposome, an activated dendrimer, a large multilamellar liposomal vesicle, and a protein/amphipathic polyamine complex. The effect was seen regardless of the cellular expression of the adenovirus receptor, CAR, in three different human cancer cell lines derived from rhabdomyosarcomas (Rh18 and RD, CAR-) and cervical carcinoma (HeLa, CAR+). The protein/amphipathic polyamine complex showed an adenofection effect but did not show a lipoduction effect, consistent with different mechanisms of action for adenofection and lipoduction. Using dual-color flow cytometric analysis of cells transfected with a plasmid expressing the enhanced blue fluorescent protein (pEBFP) and a recombinant adenovirus expressing the green fluorescent protein (Ad5-GFP), we demonstrate that adenofection works primarily by increasing gene expression within a cell, whereas lipoduction increases the percentage of cells expressing the transgene. In addition, these studies show that both adenofection and lipoduction can occur simultaneously, further increasing gene transfer. The combination of lipofection and adenovirus transduction also prolonged the duration of transient gene expression and was generally no more toxic than lipofection alone. The enhancement of gene transfer was also seen after injection of complexes directly into subcutaneous human xenograft tumors. Therefore, more effective gene transfer in vitro and in vivo of either plasmid DNA, adenovirus DNA, or both can be achieved by combining liposomal transfection with adenoviral transduction.

journal_name

Hum Gene Ther

journal_title

Human gene therapy

authors

Dunphy EJ,Redman RA,Herweijer H,Cripe TP

doi

10.1089/10430349950017059

keywords:

subject

Has Abstract

pub_date

1999-09-20 00:00:00

pages

2407-17

issue

14

eissn

1043-0342

issn

1557-7422

journal_volume

10

pub_type

杂志文章
  • The Future Looks Brighter After 25 Years of Retinal Gene Therapy.

    abstract::The first report of in vivo gene delivery to the retina dates back to 1987 when a retroviral vector was injected intraocularly in newborn mice. Later came the observation that retinal cells could be successfully transduced using adenoviral and then adeno-associated and lentiviral vectors. By 2000, it had become clear ...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2017.164

    authors: Auricchio A,Smith AJ,Ali RR

    更新日期:2017-11-01 00:00:00

  • Differentiation and expansion of lentivirus vector-marked dendritic cells derived from human CD34(+) cells.

    abstract::The in vitro genetic manipulation of dendritic cells (DCs) for the expression of foreign proteins or peptides will assist in the development of immunotherapeutic approaches to treat cancer, immunological disorders, and/or infectious diseases. Reports have shown the expansion and differentiation of CD34(+) progenitor c...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050207975

    authors: Evans JT,Cravens P,Lipsky PE,Garcia JV

    更新日期:2000-12-10 00:00:00

  • Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery.

    abstract::The potential of short interfering RNA (siRNA) to be developed for therapeutic use against cancer depends on the availability of an efficient tumor-specific delivery vehicle. We have previously shown that a nanoscale nonviral liposome-based complex that includes an anti-transferrin receptor single-chain antibody fragm...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.17.117

    authors: Pirollo KF,Zon G,Rait A,Zhou Q,Yu W,Hogrefe R,Chang EH

    更新日期:2006-01-01 00:00:00

  • Enhancing Graduate and Postdoctoral Education To Create a Sustainable Biomedical Workforce.

    abstract::PhD-trained biomedical scientists are moving into an increasingly diverse variety of careers within the sciences. However, graduate and postdoctoral training programs have historically focused on academic career preparation, and have not sufficiently prepared trainees for transitioning into other scientific careers. A...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2016.154

    authors: Fuhrmann CN

    更新日期:2016-11-01 00:00:00

  • The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines.

    abstract::Human serum is known to inactivate many retroviruses, including murine leukemia viruses (MLV). Exposure of vectors based on MLV to human serum components would presumably decrease the efficiency of gene transfer in vivo. Human serum also lyses xenogeneic cells, which would affect the survival of retroviral vector pack...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.5-635

    authors: Russell DW,Berger MS,Miller AD

    更新日期:1995-05-01 00:00:00

  • FUT-175, a synthetic inhibitor of the complement pathway, protects against the inactivation of infectious retroviruses by human serum.

    abstract::Serum-induced inactivation of retroviruses is the most critical limitation for in vivo gene transfer therapy. To solve this problem, we searched for reagents that protect retroviruses from inactivation. The effects of the protease inhibitors FOY-007 and FOY-305 and of an inhibitor of the complement pathway FUT-175, al...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.13-1575

    authors: Miyao Y,Ikenaka K,Kishima H,Tamura M,Nakamura K,Kurumi M,Hayakawa T,Shimizu K

    更新日期:1997-09-01 00:00:00

  • Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells.

    abstract::Clinical trials of gene therapy using a viral delivery system for glioma have been limited. Recently, gene therapy using stem cells as the vehicles for delivery of therapeutic agents has emerged as a new treatment strategy for malignant brain tumors. In this study, we used human umbilical cord blood-derived mesenchyma...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2010.187

    authors: Ryu CH,Park SH,Park SA,Kim SM,Lim JY,Jeong CH,Yoon WS,Oh WI,Sung YC,Jeun SS

    更新日期:2011-06-01 00:00:00

  • Highly efficient adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery.

    abstract::Efficient and homogeneous gene transfer to cardiac myocytes is a major target in myocardial gene therapy. The aim of this study was to determine the conditions permitting efficient, homogeneous, adenovirus-mediated gene transfer to cardiac myocytes, with a view to application during coronary artery catheterization. Ge...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050015329

    authors: Logeart D,Hatem SN,Rücker-Martin C,Chossat N,Névo N,Haddada H,Heimburger M,Perricaudet M,Mercadier JJ

    更新日期:2000-05-01 00:00:00

  • Potential of allospecific gene-engineered T cells in transplantation gene therapy: specific T cell activation determines transgene expression in vitro and in vivo.

    abstract::T lymphocytes, regardless of their specificity, are considered key targets for genetic modification in the treatment of inherited or acquired human diseases. In this study, we generated Lewis T cell lines specific for Dark Agouti rat alloantigens and tested the potential of allospecific T lymphocytes as carriers of ge...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050032401

    authors: Hammer MH,Flügel A,Seifert M,Lehmann M,Brandt C,Volk HD,Ritter T

    更新日期:2000-06-10 00:00:00

  • Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.

    abstract::The immune response against human immunodeficiency virus type-1 (HIV-1) is believed to play a role in controlling the early stages of disease progression. The cellular immune response, in particular cytotoxic T lymphocyte (CTL) activity, may be important for eliminating virally infected cells in HIV-1-infected individ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1994.5.7-853

    authors: Laube LS,Burrascano M,Dejesus CE,Howard BD,Johnson MA,Lee WT,Lynn AE,Peters G,Ronlov GS,Townsend KS

    更新日期:1994-07-01 00:00:00

  • Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.

    abstract::Mucopolysaccharidosis type IIIA (MPSIIIA) is a rare lysosomal storage disorder caused by mutations in the sulfamidase gene. Accumulation of glycosaminoglycan (GAG) inside the lysosomes is associated with severe neurodegeneration as well as peripheral organ pathological changes leading to death of affected individuals ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2012.029

    authors: Ruzo A,Marcó S,García M,Villacampa P,Ribera A,Ayuso E,Maggioni L,Mingozzi F,Haurigot V,Bosch F

    更新日期:2012-12-01 00:00:00

  • Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells.

    abstract::Fabry disease, caused by a deficiency of lysosomal enzyme alpha-galactosidase A (alpha-gal A), is one of the inherited disorders potentially treatable by gene transfer to hematopoietic stem cells. In this study, a high-titer amphotropic retroviral producer cell line, MFG-alpha-gal A, was established. CD34+ cells from ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950016302

    authors: Takiyama N,Dunigan JT,Vallor MJ,Kase R,Sakuraba H,Barranger JA

    更新日期:1999-12-10 00:00:00

  • Rescue of Adeno-Associated Virus Production by shRNA Cotransfection.

    abstract::Adeno-associated virus (AAV) vector technology is rapidly advancing and becoming not only the leading vector platform in the field of gene therapy but also a useful tool for functional genomic studies of novel proteins. As most vectors utilize constitutive promoters, this results in transgene expression during product...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2019.249

    authors: Guimaro MC,Afione SA,Tanaka T,Chiorini JA

    更新日期:2020-10-01 00:00:00

  • Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases.

    abstract::Adeno-associated viral (AAV) vectors containing cone-specific promoters have rescued cone photoreceptor function in mouse and dog models of achromatopsia, but cone-specific promoters have not been optimized for use in primates. Using AAV vectors administered by subretinal injection, we evaluated a series of promoters ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2015.130

    authors: Ye GJ,Budzynski E,Sonnentag P,Nork TM,Sheibani N,Gurel Z,Boye SL,Peterson JJ,Boye SE,Hauswirth WW,Chulay JD

    更新日期:2016-01-01 00:00:00

  • Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.

    abstract::Production of clinical-grade gammaretroviral vectors for ex vivo gene delivery requires a scalable process that can rapidly generate large amounts of vector supernatant, clear large numbers of residual packaging cells with minimal decreases in vector titer, and satisfy all current regulatory guidelines regarding produ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2010.064

    authors: Feldman SA,Goff SL,Xu H,Black MA,Kochenderfer JN,Johnson LA,Yang JC,Wang Q,Parkhurst MR,Cross S,Morgan RA,Cornetta K,Rosenberg SA

    更新日期:2011-01-01 00:00:00

  • Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route.

    abstract::Duchenne muscular dystrophy (DMD) and other inherited myopathies lead to progressive destruction of most skeletal muscles in the body, including those responsible for maintaining respiration. DMD is a fatal disorder caused by defects in the dystrophin gene. Recombinant adenovirus vectors (AdV) are considered a promisi...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050015608

    authors: Cho WK,Ebihara S,Nalbantoglu J,Gilbert R,Massie B,Holland P,Karpati G,Petrof BJ

    更新日期:2000-03-20 00:00:00

  • Escherichia coli-cloned CFTR loci relevant for human artificial chromosome therapy.

    abstract::Classical gene therapy for cystic fibrosis has had limited success because of immune response against viral vectors and short-term expression of cDNA-based transgenes. These limitations could be overcome by delivering the complete genomic CFTR gene on nonintegrating human artificial chromosomes (HACs). Here, we report...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2009.225

    authors: Rocchi L,Braz C,Cattani S,Ramalho A,Christan S,Edlinger M,Ascenzioni F,Laner A,Kraner S,Amaral M,Schindelhauer D

    更新日期:2010-09-01 00:00:00

  • Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.

    abstract::MDA-MB-231, an HLA-A2(+), HER2/neu(+) allogeneic breast cancer cell line genetically modified to express the costimulatory molecule CD80 (B7-1), was used to vaccinate 30 women with previously treated stage IV breast cancer. Expression of CD80 conferred the ability to deliver a costimulatory signal and thereby improved...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章

    doi:10.1089/104303403322124828

    authors: Dols A,Smith JW 2nd,Meijer SL,Fox BA,Hu HM,Walker E,Rosenheim S,Moudgil T,Doran T,Wood W,Seligman M,Alvord WG,Schoof D,Urba WJ

    更新日期:2003-07-20 00:00:00

  • Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial.

    abstract::Recombinant vectors based on adeno-associated virus serotype 8 (AAV8) have been successfully used in the clinic and hold great promise for liver-directed gene therapy. Preexisting immunity against AAV8 or the development of antibodies against the therapeutic transgene product might negatively affect the outcomes of ge...

    journal_title:Human gene therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1089/hum.2014.109

    authors: Ferla R,Claudiani P,Savarese M,Kozarsky K,Parini R,Scarpa M,Donati MA,Sorge G,Hopwood JJ,Parenti G,Fecarotta S,Nigro V,Sivri HS,Van Der Ploeg A,Andria G,Brunetti-Pierri N,Auricchio A

    更新日期:2015-03-01 00:00:00

  • Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice.

    abstract::Atrogin-1 or muscle atrophy F-box (MAFbx) is a major atrophy-related E3 ubiquitin ligase highly expressed in skeletal muscle during muscle atrophy and other disease states such as sepsis, cancer cachexia, and fasting. In this paper, we report experiments inhibiting MAFbx activity in fasting mice and in the skeletal my...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2010.057

    authors: Cong H,Sun L,Liu C,Tien P

    更新日期:2011-03-01 00:00:00

  • Ultrasound enhances gene delivery of human factor IX plasmid.

    abstract::Delivery of plasmid DNA can be enhanced by treatment with ultrasound (US); acoustic cavitation appears to play an important role in the process. Ultrasound contrast agents (UCAs; stabilized microbubbles) nucleate acoustic cavitation, and lower the acoustic pressure threshold for inertial cavitation occurrence. Fifty m...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2005.16.893

    authors: Miao CH,Brayman AA,Loeb KR,Ye P,Zhou L,Mourad P,Crum LA

    更新日期:2005-07-01 00:00:00

  • CRISPR/Cas9 Editing: Sparking Discussion on Safety in Light of the Need for New Therapeutics.

    abstract::Recent advances in genome sequencing have greatly improved our ability to understand and identify the causes of genetic diseases. However, there remains an urgent need for innovative, safe, and effective treatments for these diseases. CRISPR-based genome editing systems have become important and powerful tools in the ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.111

    authors: Carlaw TM,Zhang LH,Ross CJD

    更新日期:2020-08-01 00:00:00

  • Recombinant adeno-associated viral vectors in the nervous system.

    abstract::Recombinant adeno-associated virus 2 (rAAV2) has been extensively used as a gene delivery vector for the nervous system. It targets primarily neurons in the nervous system and results in sustained long-term expression of transgenes. New rAAV serotypes have been characterized and demonstrated to have improved transduct...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2005.16.781

    authors: Burger C,Nash K,Mandel RJ

    更新日期:2005-07-01 00:00:00

  • Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one.

    abstract::The T cell co-stimulatory molecule B7-1 was transduced into a poorly immunogenic murine neuroblastoma cell line (Neuro-2a, N-2a) alone or in combination with MHC class II genes to test the ability of these genes to stimulate antitumor immunity. N-2a cells transduced with B7-1 exhibited reduced tumorigenicity, whereas ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.17-2059

    authors: Heuer JG,Tucker-McClung C,Gonin R,Hock RA

    更新日期:1996-11-10 00:00:00

  • Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial.

    abstract::Twenty-eight patients with advanced neovascular age-related macular degeneration (AMD) were given a single intravitreous injection of an E1-, partial E3-, E4-deleted adenoviral vector expressing human pigment epithelium- derived factor (AdPEDF.11). Doses ranging from 10(6) to 10(9.5) particle units (PU) were investiga...

    journal_title:Human gene therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1089/hum.2006.17.167

    authors: Campochiaro PA,Nguyen QD,Shah SM,Klein ML,Holz E,Frank RN,Saperstein DA,Gupta A,Stout JT,Macko J,DiBartolomeo R,Wei LL

    更新日期:2006-02-01 00:00:00

  • Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors.

    abstract::Adenoviruses are attractive vectors for gene transfer into cardiac muscle. However, their promiscuous tissue tropism, which leads to an ectopic expression of the transgene, is a considerable limitation. To restrict expression to cardiomyocytes, we have constructed two recombinant adenoviruses (Ad-MLC2-250betagal and A...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.13-1919

    authors: Griscelli F,Gilardi-Hebenstreit P,Hanania N,Franz WM,Opolon P,Perricaudet M,Ragot T

    更新日期:1998-09-01 00:00:00

  • A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors.

    abstract::The efficiency of gene therapy strategies against cancer is limited by the poor distribution of the vectors in the malignant tissues. To solve this problem, a new generation of tumor-specific, conditionally replicative adenoviruses is being developed. To direct the replication of the virus to breast cancer, we have co...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050143435

    authors: Hernandez-Alcoceba R,Pihalja M,Wicha MS,Clarke MF

    更新日期:2000-09-20 00:00:00

  • A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.

    abstract::Interleukin (IL)-12 has been reported to induce cellular immune responses for protection against tumor formation. Here we investigate the utility of adenoviral delivery of IL-12 as an adjuvant for a human papillomavirus E7 subunit vaccine in a mouse tumor challenge model. Direct intratumoral injection of AdIL-12 resul...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303403769211619

    authors: Ahn WS,Bae SM,Kim TY,Kim TG,Lee JM,Namkoong SE,Kim CK,Sin JI

    更新日期:2003-10-10 00:00:00

  • Multicompartment, numerical model of cellular events in the pharmacokinetics of gene therapies.

    abstract::DNA expression vectors may be administered to patients like conventional medicines to have a finite and controlled duration of action. The clinical application of these medicines will require a precise understanding of the kinetics of the administered gene, the mRNA transcript, and the gene product. The apparent kinet...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1994.5.6-679

    authors: Ledley TS,Ledley FD

    更新日期:1994-06-01 00:00:00

  • Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.

    abstract::Establishing pharmacological parameters, such as efficacy, routes of administration, and toxicity, for recombinant adeno-associated virus (rAAV) vectors is a prerequisite for gaining acceptance for clinical applications. In fact, even a therapeutic window, that is, the dose range between therapeutic efficacy and toxic...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2009.092

    authors: Virag T,Cecchini S,Kotin RM

    更新日期:2009-08-01 00:00:00